2020 Nelson's Pediatric Antimicrobial Therapy

Description

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices. Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens. New in the 26th edition: First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates) Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections Updates on management of influenza, including baloxavir (now approved for children >12 years) New approaches to treatment of mucomycosis New recommendations for malaria More than 150 new references!